Author

Monique Carter

Observed name: M Carter

Institution: Pfizer (United States)

Observed institutions: Pfizer (United States), Arog Pharmaceuticals (United States), University of Delaware, The University of Texas Southwestern Medical Center

ORCID: 0000-0002-2749-9513

Observed ORCID: 0000-0002-2749-9513

OpenAlex ID: A5028772847

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)

2017 · Madhura Joglekar-Javadekar, Steven Van Laere, et al. · Neoplasia · 71

Hox and a Newly Identified E2F Co-repress Cell Death in Caenorhabditis elegans

2011 · Jennifer Winn, Monique Carter, et al. · Genetics · 34

European Medicines Agency‐Health Technology Assessment Parallel Consultation Platform: An Industry Perspective

2019 · Saima Khan, Monique Carter · Clinical Pharmacology & Therapeutics · 6

Novel–novel fixed-dose combination therapies

2019 · Monique Carter, Saima Khan · Nature Reviews Drug Discovery · 1

Abstract P6-12-15: Preclinical testing of a novel platelet derived growth factor receptor alpha (PDGFRa) inhibitor in inflammatory breast cancer

2013 · M Joglekar, S Van Laere, et al. · Cancer Research

Abstract 1035: Crenolanib, a highly selective platelet-derived growth factor receptor α/β (PDGFRA/B) tyrosine kinase inhibitor, destabilizes ETV1 protein in KIT-mutant gastrointestinal stromal tumor (GIST) cells.

2013 · Yujiro Hayashi, Michael R. Bardsley, et al. · Cancer Research

Abstract 4282: Crenolanib inhibition of PDGFRA+ fibroblast-like cells in visceral smooth muscle.

2013 · Evan Colletti, Abhijit Ramachandran, et al. · Cancer Research

Works count: 7

Citation count: 112

H-index: 3

I10-index: 2